Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r
Randomized, Open-label Study of Switch From Lopinavir/Ritonavir (LPV/r) or Fosamprenavir/Ritonavir (FPV/r) to Either Once Daily Atazanavir/Ritonavir (ATV/r) or Once Daily Darunavir/Ritonavir (DRV/r) (Plus Background Nucleoside Reverse Transcriptase Inhibitors) in Patients Experiencing Triglyceride Elevations While Receiving LPV/r or FPV/r.
Sponsor: Community Research Initiative of New England
A PHASE4 clinical study on HIV Infections, this trial is completed. The trial is conducted by Community Research Initiative of New England and has accumulated 7 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Community Research Initiative of New England
- Tibotec Pharmaceutical Limited
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boston, United States
- • Dallas, United States
- • Los Angeles, United States
- • Milwaukee, United States
- • Minneapolis, United States
- • Orlando, United States
- • Philadelphia, United States
- • Phoenix, United States
- • Rochester, United States
- • Springfield, United States